Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

The advent of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of patients with locally advanced unresectable and metastatic non-small cell lung cancer (NSCLC). Now, ICIs are undergoing evaluation as neoadjuvant therapy in patients with early-stage, resectable NSCLC using c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradhan, Monika, Chocry, Mathieu, Gibbons, Don L., Sepesi, Boris, Cascone, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Articles on Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867746/
https://www.ncbi.nlm.nih.gov/pubmed/33569339
http://dx.doi.org/10.21037/tlcr-20-573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867746/
https://www.ncbi.nlm.nih.gov/pubmed/33569339
http://dx.doi.org/10.21037/tlcr-20-573

Ejemplares similares